Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy Context: From General Health to Occupational Exposure

General health and science communication has long served as a bridge between complex biomedical information and public understanding. In this legacy context, discussions of medication safety, bone health, and oral care have been framed for broad audiences, emphasizing prevention and informed patient-provider dialogue. The transition from this general health heritage to a more focused occupational exposure concern requires careful attention to the shift in perspective—from population-level awareness to specific, work-related risk considerations. In mass production environments, workers may encounter materials and processes that differ substantially from typical consumer or patient experiences. The pivot from general health information to occupational exposure concern involves recognizing that workplace settings can introduce unique pathways of contact with substances, including pharmaceuticals or their precursors. For instance, while the general public might encounter bisphosphonate medications like Fosamax through prescription use, industrial settings could involve handling of raw materials, manufacturing byproducts, or concentrated forms that present distinct exposure profiles. This shift demands a reorientation of the risk assessment framework: instead of focusing on therapeutic dosing and patient compliance, the emphasis moves to inhalation, dermal contact, or accidental ingestion during production, packaging, or maintenance activities. The occupational lens thus transforms the conversation from one of informed patient choice to one of workplace safety protocols, exposure monitoring, and regulatory compliance—a necessary evolution when moving from general health literacy to protecting those who manufacture the very products that enter the healthcare system.

Bridging to Fosamax and ONJ

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw that can occur spontaneously or following dental procedures. Clinical presentation and diagnosis of ONJ typically involve areas of exposed bone in the mandible or maxilla, often with pain, swelling, infection, or delayed healing after tooth extraction or other invasive dental treatments. The condition is generally associated with local infection and delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis relies on clinical examination and imaging, with a focus on ruling out other causes of jaw necrosis, such as malignancy or radiation therapy.

Mechanistic Pathways Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate. Bisphosphonates inhibit osteoclast-mediated bone resorption, which can suppress normal bone turnover and remodeling. In the jawbone, which has high vascularity and rapid turnover, this suppression may impair the ability to repair microdamage and respond to infection or trauma. Multiscale characterization of jawbone provides information that helps understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests that the unique structure and physiology of the jaw make it particularly vulnerable to bisphosphonate-induced complications.

Risk Factors and Clinical Evidence

Risk factors for developing ONJ while taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of exposure to bisphosphonates. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's labeling. The prescribing information includes a specific warning under section 5.4, "Osteonecrosis of the Jaw," which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also notes that ONJ can occur spontaneously and is generally associated with tooth extraction and/or local infection with delayed healing. Known risk factors are listed, and the potential for increased risk with longer exposure is mentioned. However, the labeling does not provide specific incidence rates for ONJ in Fosamax users, and in placebo-controlled clinical studies, the percentages of patients with jaw-related symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse event, its occurrence may be rare and influenced by individual risk factors.

Causation Considerations for Affected Patients

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax use and the development of ONJ. The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, but a subset may have recurrence if rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal link, though other factors such as dental procedures or infections may contribute. For patients with ONJ, evaluation should include a thorough dental examination and consideration of alternative causes. The timeline between exposure and documented harm can be variable. ONJ may develop within days to months after starting Fosamax, but it is more commonly reported after longer-term use, particularly in patients with additional risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk appears to increase with cumulative exposure, and the optimal duration of Fosamax use has not been determined; for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This highlights the importance of periodic reassessment of the need for continued therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it used?

What is osteonecrosis of the jaw (ONJ) and how is it diagnosed?

ONJ is a condition characterized by exposed, non-healing bone in the jaw, often with pain, swelling, infection, or delayed healing after dental procedures. Diagnosis relies on clinical examination and imaging to rule out other causes (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.